Novartis

Light Horse lassos Novartis partnership worth up to $1B, wrangles $62M series A
Fierce Biotech
Thu, 01/9/25 - 09:29 pm
Novartis
Light Horse Therapeutics
funding
biobucks
genetic screening
Positive data could expand use of Novartis’ gene therapy for SMA
Clinical Trials Arena
Fri, 01/3/25 - 11:02 am
Novartis
gene therapy
SMA
Zolgensma
OAV101 IT
Novartis’ Phase III spinal muscular atrophy therapy trial meets primary endpoint
Clinical Trials Arena
Thu, 01/2/25 - 11:25 am
Novartis
clinical trials
gene therapy
spinal muscular atrophy
SMA
OAV101 IT
Novartis to shutter 2 MorphoSys sites, lay off 330 staffers in post-buyout consolidation
Fierce Pharma
Thu, 12/19/24 - 10:11 am
Novartis
MorphoSys
layoffs
UCB's orchestra hits dud note: Novartis-partnered Parkinson's asset fails phase 2
Fierce Biotech
Tue, 12/17/24 - 11:58 am
UCB Pharma
Novartis
Parkinson's Disease
minzasolmin
clinical trials
ICER calls out Gilead, J&J, Novartis and more in latest report on 'unsupported' price increases
Fierce Pharma
Thu, 12/12/24 - 11:44 pm
ICER
drug pricing
Gilead Sciences
JNJ
Novartis
Can CAR-T first movers keep pace in a rapidly evolving market?
Pharmaphorum
Wed, 12/11/24 - 10:59 am
CAR-T
Gilead Sciences
Novartis
Novartis reports topline outcomes from Phase IIIB PNH trial of Fabhalta
Clinical Trials Arena
Mon, 12/9/24 - 10:41 am
Novartis
Fabhalta
PNH
clinical trials
Novartis bid to block generic Entresto in US suffers setback
Pharmaphorum
Thu, 12/5/24 - 11:01 am
Novartis
Entresto
legal
generics
heart failure
Novartis wagers billions of dollars on PTC Huntington’s drug
BioPharma Dive
Mon, 12/2/24 - 11:26 am
Novartis
PTC Therapeutics
Huntington's disease
PTC518
Olema stock surges on Novartis deal and $250M private placement
Investing.com
Mon, 12/2/24 - 11:09 am
Olema
Novartis
breast cancer
Novartis plots more than 100 layoffs in New Jersey as part of rework to Xolair, cancer combo field sales teams
Fierce Pharma
Tue, 11/26/24 - 10:26 pm
Novartis
layoffs
New Jersey
Xolair
Novartis buys Kate Therapeutics, eyeing $55B CGT market opportunity by 2030
BioSpace
Thu, 11/21/24 - 11:54 am
Novartis
Kate Therapeutics
M&A
gene therapy
Novartis: launch of Morphosys drug by could be 2027 or later
Pharma Live
Thu, 11/21/24 - 11:43 am
Novartis
pelabresib
MorphoSys
obesity
Novartis taps Vyriad’s viral vectors to develop in vivo T cell editing
Fierce Biotech
Wed, 11/20/24 - 08:44 pm
Novartis
Vyriad
viral vectors
t cell therapy
CAR-T
Novartis, Ratio sign radiopharmaceutical pact to the tune of $745M biobucks
Fierce Biotech
Mon, 11/18/24 - 11:32 am
Novartis
radiopharmaceuticals
Ration Therapeutics
biobucks
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
CP Wire
Thu, 11/14/24 - 10:25 pm
Azurity
Danziten
Ph+ CML
FDA
Novartis
Tasigna
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Thu, 11/14/24 - 07:28 pm
Azurity
Danziten
Ph+ CML
FDA
Novartis
Tasigna
Novartis pays Schrödinger $150M, bets billions on the back end to form drug discovery pact
Fierce Biotech
Tue, 11/12/24 - 11:02 am
Novartis
Schrödinger
R&D
Autolus enters CAR-T race with FDA approval for Aucatzyl
Fierce Pharma
Mon, 11/11/24 - 11:49 am
Autolus Therapeutics
CAR-T
FDA
Aucatzyl
Gilead Sciences
Novartis
relapsed or refractory B-cell precursor acute lymphoblastic leukemia

Pages